ICLUSIG (ponatinib) safety profile

Ponatinib safety profile in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) 
and chronic phase chronic myeloid leukemia (CP-CML)

The ICLUSIG (ponatinib) safety profile has been characterized across three pivotal trials: OPTIC and PACE in CP-CML and Ph+ ALL; and PhALLCON in newly diagnosed Ph+ ALL. ICLUSIG is supported in both indications by an optimized, response-based dosing strategy designed to manage tolerability.1-4

ICLUSIG carries a Boxed Warning for arterial occlusive events, venous thromboembolic events, heart failure, and hepatotoxicity.

ICLUSIG is supported by an established dataset. The program spans PhALLCON—the first head-to-head phase 3 clinical trial vs another TKI in adults with newly diagnosed Ph+ ALL—and the OPTIC and PACE trials in  CP-CML.1-4 Together, these trials provide more than 5 years of efficacy follow-up in CP-CML and pivotal frontline data in Ph+ ALL.3,4

Ph+ ALL.

In adults with newly diagnosed Ph+ ALL, PhALLCON established an optimized dose-reduction strategy (30 mg → 15 mg for patients who achieve an MRD-negative CR at the end of induction) in combination with chemotherapy, with ICLUSIG + chemotherapy providing a comparable safety profile to imatinib + chemotherapy.1,2 PACE provides long-term safety follow-up in heavily pretreated patients.1,4

CP-CML.

In CP-CML, OPTIC established an optimized dose-reduction strategy (45 mg → 15 mg upon achievement of ≤1% BCR::ABL1IS), and by Year 5 the OPTIC safety results were consistent with those of the primary analysis.1,3,4 PACE provides long-term safety follow-up in heavily pretreated patients.1,4

Please review the full Important Safety Information, including the Boxed Warning, and the full Prescribing Information.1


ICLUSIG efficacy data in Ph+ ALL

ICLUSIG efficacy data in CP-CML